On Saturday, Beam Therapeutics Inc. (NASDAQ:BEAM) revealed new safety and efficacy data from its BEACON Phase 1/2 trial of BEAM-101 in patients with sickle cell disease (SCD) with severe vaso-occlusive crises (VOCs).
The data were featured at the American Society of Hematology (ASH) Annual Meeting and Exposition.
Consistent with Beam’s previously announced data, updated data from seven patients treated with investigational base-editing therapy BEAM-101 demonstrated robust and durable increases in fetal hemoglobin (HbF) and reductions in sickle hemoglobin (HbS), rapid neutrophil and platelet engraftment, and normalized or improved markers of hemolysis.
No VOCs were reported post-engraftment.
Key highlights include the following:
In November, the company said that one patient died due to respiratory failure likely related to busulfan conditioning four months after BEAM-101 infusion. However, the investigator determined that the death was unrelated to BEAM-101.
On Sunday, Beam Therapeutics announced new data for its Engineered Stem Cell Antibody Evasion (ESCAPE) conditioning platform, which was presented at the American Society of Hematology Annual Meeting and Exposition.
ESCAPE comprises two investigational drug products, BEAM-103 and BEAM-104. The company intends to advance BEAM-103 and BEAM-104 for development in sickle cell disease and beta-thalassemia.
In the preclinical study, administration of the BEAM-104 edited cells to antibody-conditioned animals led to long-term engraftment.
Dosing with the BEAM-103 mAb led to rapid and near complete replacement of wild-type erythroid cells by edited cells, leading to early induction of therapeutically relevant levels of HbF.
BEAM-103 dosing was well tolerated, with no need for transfusions, antibiotics, or additional supportive care.
William Blair writes, “While the patient death is unfortunate, we see the event as highlighting the need for less-toxic preconditioning options, and we think Beam is leading the space in this regard.”
Price Action: At last check on Monday, BEAM stock was up 0.52% at $26.89.
Read Next:
Date | Firm | Action | From | To |
---|---|---|---|---|
Jan 2022 | SVB Leerink | Maintains | Outperform | |
Jan 2022 | Guggenheim | Initiates Coverage On | Buy | |
Nov 2021 | SVB Leerink | Maintains | Outperform |
View More Analyst Ratings for BEAM
View the Latest Analyst Ratings
Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.
Get the latest stock analysis from Benzinga?
This article Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains originally appeared on Benzinga.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。